{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:42:06Z","timestamp":1790883726010,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,8,4]],"date-time":"2007-08-04T00:00:00Z","timestamp":1186185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2007,9,6]]},"DOI":"10.1007\/s00228-007-0350-0","type":"journal-article","created":{"date-parts":[[2007,8,3]],"date-time":"2007-08-03T12:29:18Z","timestamp":1186144158000},"page":"941-949","source":"Crossref","is-referenced-by-count":41,"title":["Voriconazole and fluconazole increase the exposure to oral diazepam"],"prefix":"10.1007","volume":"63","author":[{"given":"Teijo I.","family":"Saari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus T.","family":"Olkkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,4]]},"reference":[{"issue":"1","key":"350_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1213\/00000539-198301000-00001","volume":"62","author":"M Divoll","year":"1983","unstructured":"Divoll M, Greenblatt DJ, Ochs HR, Shader RI (1983) Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg 62(1):1\u20138","journal-title":"Anesth Analg"},{"issue":"4","key":"350_CR2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/clpt.1989.40","volume":"45","author":"L Bertilsson","year":"1989","unstructured":"Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45(4):348\u2013355","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"350_CR3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1994.tb04336.x","volume":"38","author":"T Andersson","year":"1994","unstructured":"Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38(2):131\u2013137","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"350_CR4","first-page":"133","volume":"25","author":"F Jung","year":"1997","unstructured":"Jung F, Richardson TH, Raucy JL, Johnson EF (1997) Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos 25(2):133\u2013139","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"350_CR5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0090-9556(24)14891-X","volume":"27","author":"TJ Yang","year":"1999","unstructured":"Yang TJ, Krausz KW, Sai Y, Gonzales FJ, Gelboin HV (1999) Eight inhibitory monoclonal antibodies define the role of individual P-450s in human microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos 27(1):102\u2013109","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"350_CR6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2165\/00003088-199018060-00002","volume":"18","author":"S Caccia","year":"1990","unstructured":"Caccia S, Garattini S (1990) Formation of active metabolites of psychotropic drugs: an updated review of their significance. Clin Pharmacokinet 18(6):434\u2013459","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"350_CR7","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","volume":"64","author":"HW Boucher","year":"2004","unstructured":"Boucher HW, Groll AH, Chiou CC, Walsh TJ (2004) Newer systemic antifungal agents. Pharmacokinetics, safety and efficacy. Drugs 64(18):1997\u20132020","journal-title":"Drugs"},{"issue":"7","key":"350_CR8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45(7):649\u2013663","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"350_CR9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD (2003) Voriconazole, a novel wide spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 56(Suppl 1):10\u201316","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"350_CR10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","volume":"31","author":"R Hyland","year":"2003","unstructured":"Hyland R, Jones BC, Smith DA (2003) Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metabol Dispos 31(5):540\u2013547","journal-title":"Drug Metabol Dispos"},{"issue":"4","key":"350_CR11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mcp.2002.121911","volume":"71","author":"AJ Romero","year":"2002","unstructured":"Romero AJ, Le Pogamp P, Nilsson L-G, Wood N (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 71(4):226\u2013234","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"350_CR12","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1128\/AAC.01483-05","volume":"50","author":"VV Hynninen","year":"2006","unstructured":"Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, Valtonen M, Vyyrylainen H, Laine K (2006) Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(\u2212)-Ibuprofen. Antimicrob Agents Chemother 50(6):1967\u20131972","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"350_CR13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","volume":"79","author":"TI Saari","year":"2006","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2006) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79(4):362\u2013370","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"350_CR14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.clpt.2006.07.008","volume":"80","author":"TI Saari","year":"2006","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2006) Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 80(5):502\u2013508","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"350_CR15","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1248\/cpb.40.1247","volume":"40","author":"K Morita","year":"1992","unstructured":"Morita K, Konishi H, Shimakawa H (1992) Fluconazole: a potent inhibitor of cytochrome P-450-dependent drug-metabolism in mice and humans in vivo. Comparative study with ketoconazole. Chem Pharm Bull (Tokyo) 40(5):1247\u20131251","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"5","key":"350_CR16","first-page":"610","volume":"24","author":"LC Wienkers","year":"1996","unstructured":"Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF (1996) Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 24(5):610\u2013614","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"350_CR17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28(9):1805\u20131808","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"350_CR18","first-page":"511","volume":"82","author":"KT Olkkola","year":"1996","unstructured":"Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82(3):511\u2013516","journal-title":"Anesth Analg"},{"issue":"4","key":"350_CR19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2125.1996.03189.x","volume":"41","author":"A Varhe","year":"1996","unstructured":"Varhe A, Olkkola KT, Neuvonen PJ (1996) Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41(4):319\u2013323","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"350_CR20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1213\/00000539-199807000-00039","volume":"87","author":"VJ Palkama","year":"1998","unstructured":"Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT (1998) The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 87(1):190\u2013194","journal-title":"Anesth Analg"},{"issue":"6","key":"350_CR21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/0016-5085(85)90638-9","volume":"89","author":"R Gugler","year":"1985","unstructured":"Gugler R, Jensen JC (1985) Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89(6):1235\u20131241","journal-title":"Gastroenterology"},{"issue":"5","key":"350_CR22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/clpt.1994.167","volume":"56","author":"E Perucca","year":"1994","unstructured":"Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56(5):471\u2013476","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"350_CR23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0773.1996.tb00191.x","volume":"78","author":"H Luurila","year":"1996","unstructured":"Luurila H, Olkkola KT, Neuvonen PJ (1996) Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacol Toxicol 78(2):117\u2013122","journal-title":"Pharmacol Toxicol"},{"issue":"3","key":"350_CR24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1472-8206.1996.tb00312.x","volume":"10","author":"J Ahonen","year":"1996","unstructured":"Ahonen J, Olkkola KT, Neuvonen PJ (1996) The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 10(3):314\u2013318","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"350_CR25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0378-4347(91)80099-X","volume":"564","author":"T Stebler","year":"1991","unstructured":"Stebler T, Guentert TW (1991) Determination of diazepam and nordazepam in milk and plasma in the presence of oxazepam and temazepam. J Chromatogr 564(1):330\u2013337","journal-title":"J Chromatogr"},{"issue":"8","key":"350_CR26","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0731-7085(98)00004-1","volume":"17","author":"R Gage","year":"1998","unstructured":"Gage R, Stopher DA (1998) A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 17(8):1449\u20131453","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"350_CR27","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1128\/AAC.47.7.2348-2350.2003","volume":"47","author":"GJ Pennick","year":"2003","unstructured":"Pennick GJ, Clark M, Sutton DA, Rinaldi MG (2003) Development and validation of HPLC assay for voriconazole. Antimicrob Agents Chemother 47(7):2348\u20132350","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"350_CR28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00007691-199208000-00008","volume":"14","author":"K Inagaki","year":"1992","unstructured":"Inagaki K, Takagi J, Lor E, Okamoto MP, Gill MA (1992) Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther Drug Monit 14(4):306\u2013311","journal-title":"Ther Drug Monit"},{"issue":"22","key":"350_CR29","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM Morais De","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269(22):15419\u201315422","journal-title":"J Biol Chem"},{"issue":"6","key":"350_CR30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen E, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(6):103\u2013113","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"350_CR31","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1111\/j.1365-2125.1984.tb02578.x","volume":"18","author":"BM Stone","year":"1984","unstructured":"Stone BM (1984) Pencil and paper tests-sensitivity to psychotropic drugs. Br J Clin Pharmacol 18(Suppl 1):15S\u201320S","journal-title":"Br J Clin Pharmacol"},{"issue":"5715","key":"350_CR32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/bmj.3.5715.132","volume":"3","author":"JG Hannington-Kiff","year":"1970","unstructured":"Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J 3(5715):132\u2013135","journal-title":"Br Med J"},{"key":"350_CR33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"A Bond","year":"1974","unstructured":"Bond A, Lader M (1974) The use of analogue visual scales in rating subjective feelings. Br J Med Psychol 47:211\u2013218","journal-title":"Br J Med Psychol"},{"issue":"1","key":"350_CR34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","volume":"54","author":"JT Backman","year":"1998","unstructured":"Backman JT, Kivist\u00f6 KT, Olkkola KT, Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54(1):53\u201358","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"350_CR35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0009-9236(99)70051-2","volume":"66","author":"VJ Palkama","year":"1999","unstructured":"Palkama VJ, Neuvonen PJ, Olkkola KT (1999) Effect of saquinavir on the pharmacokinetics and -dynamics of oral and intravenous midazolam. Clin Pharmacol Ther 66(1):33\u201339","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"350_CR36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.1981.196","volume":"30","author":"U Klotz","year":"1981","unstructured":"Klotz U, Reinman I (1981) Elevation of steady-state diazepam levels by cimetidine. Clin Pharmacol Ther 30(4):513\u2013517","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"350_CR37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00630289","volume":"26","author":"U Klotz","year":"1984","unstructured":"Klotz U, Reinman I (1984) Pharmacokinetic and pharmacodynamic interaction study of diazepam and metoprolol. Eur J Clin Pharmacol 26(2):223\u2013226","journal-title":"Eur J Clin Pharmacol"},{"issue":"25","key":"350_CR38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM198406213102505","volume":"310","author":"DJ Greenblatt","year":"1984","unstructured":"Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI (1984) Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 310(25):1639\u20131643","journal-title":"N Engl J Med"},{"issue":"4","key":"350_CR39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","volume":"52","author":"JA Goldstein","year":"2001","unstructured":"Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2c subfamily. Br J Clin Pharmacol 52(4):349\u2013355","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"350_CR40","first-page":"1195","volume":"262","author":"DR Sohn","year":"1992","unstructured":"Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T (1992) Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4\u2032-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 262(3):1195\u20131202","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"350_CR41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0009-9236(95)90193-0","volume":"58","author":"T Ishizaki","year":"1995","unstructured":"Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T (1995) Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4\u2032-hydroxylation. Clin Pharmacol Ther 58(2):155\u2013164","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"350_CR42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0009-9236(99)90075-9","volume":"66","author":"XP Qin","year":"1999","unstructured":"Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH (1999) Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 66(6):642\u2013646","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"350_CR43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clpt.2005.08.020","volume":"78","author":"S Inomata","year":"2005","unstructured":"Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y, Okuyama K, Tanaka E, Nakamura T, Kohda Y, Naito S, Miyabe M, Toyooka H (2005) CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 78(6):647\u2013655","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"350_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1067\/mcp.2000.108949","volume":"68","author":"K Laine","year":"2000","unstructured":"Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68(2):151\u2013159","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"350_CR45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2125.1996.03642.x","volume":"42","author":"RJ Herman","year":"1996","unstructured":"Herman RJ, Wilkinson GR (1996) Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol 42(2):147\u2013155","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0350-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-007-0350-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0350-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T03:29:58Z","timestamp":1737343798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-007-0350-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,4]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,9,6]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1007\/s00228-007-0350-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,4]]}}}